Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. (BCTXW) generates frequent news as a clinical-stage biotechnology company developing novel cancer immunotherapies. News about BriaCell often centers on its Bria-IMT regimen and related platforms for metastatic breast cancer, including updates from Phase 1/2, Phase 2 and pivotal Phase 3 clinical studies. Investors and observers can follow announcements on survival outcomes, safety profiles, biomarker analyses and regulatory designations related to these programs.
Recent company updates include pivotal Phase 3 trial progress in metastatic breast cancer, with information on patient screening and enrollment, interim analysis plans, and the use of overall survival as a primary endpoint. BriaCell also reports on Phase 2 survival data and biomarker findings presented at major meetings such as the San Antonio Breast Cancer Symposium, highlighting potential predictors of clinical benefit like Neutrophil-to-Lymphocyte Ratio, Delayed Type Hypersensitivity, and Th1-biased cytokine signatures.
BriaCell’s news flow further covers its Bria-OTS and Bria-OTS+ platforms, including clinical observations such as sustained complete resolution of lung metastasis in a Bria-OTS-treated metastatic breast cancer patient, and preclinical data showing rapid and durable immune activation by Bria-OTS+ candidates Bria-BRES+ and Bria-PROS+ in breast and prostate cancer models. Additional items include collaborations and pipeline expansion, such as the AI-driven small-molecule discovery partnership between BriaPro and Receptor.AI.
By following the BCTXW news page on Stock Titan, readers can review company press releases and third-party coverage related to BriaCell’s clinical milestones, scientific presentations, platform developments and strategic collaborations, all organized around this specific listed security.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has received approval from the TSX Venture Exchange for a normal course issuer bid (the “Buyback”). This allows the company to repurchase up to 1,341,515 common shares and 411,962 warrants over the next 12 months, starting September 28, 2021. This Buyback, managed by Independent Trading Group Inc., represents 10% of the public float as of September 21, 2021. The company assures that this initiative will not disrupt its growth plans in cancer immunotherapy and ongoing clinical trials.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will present at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Dr. Bill Williams, President and CEO, is scheduled to speak at 1:15 PM ET on September 29. The event will be held virtually, and investors can register for a free spectator pass. BriaCell focuses on immunotherapies for advanced breast cancer, aiming to provide targeted treatment approaches. For more details, visit briacell.com.
BriaCell Therapeutics Corp. (BCTX, BCTXW) has authorized a repurchase program for up to 1,341,515 common shares and 411,962 warrants, representing 10% of the public float. With a cash balance of US$57 million as of July 31, 2021, the buyback is expected to enhance shareholder value. The Company is advancing its cancer immunotherapy pipeline, with key studies planned for 2022. The buyback will not interfere with BriaCell's growth initiatives in cancer treatments. Independent Trading Group will manage the repurchase program, which is subject to regulatory approvals.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced the appointment of Marc Lustig to its Board of Directors, effective September 1, 2021. Lustig, a significant shareholder with 10% ownership through L5 Capital Inc., brings extensive experience in corporate finance and pharmaceuticals. He aims to enhance the company's capital markets strategy. The Board also approved a grant of 100,000 options to Lustig at C$7.24 per share, vesting immediately, with proceeds intended for donation to the Cedars Cancer Foundation.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference held virtually from September 13-15, 2021. Dr. William Williams, President & CEO, will outline the company's business during the presentation scheduled for September 13 at 7:00 A.M. (ET). Investors can access the presentation online through the provided link, with archived access for 90 days. BriaCell focuses on targeted immunotherapies for advanced breast cancer and is committed to innovative cancer management approaches.
BriaCell Therapeutics has entered into a multi-year, non-exclusive license agreement with ImaginAb to utilize its advanced CD8 ImmunoPET imaging technology for analyzing tumor-attacking CD8 T cells in breast cancer patients. This partnership supplements BriaCell's ongoing Phase I/IIa study and aims to enhance the assessment of safety and efficacy for its immunotherapy treatments. The collaboration is expected to accelerate drug development and improve patient care, with continued clinical doses and technical support from ImaginAb.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced the opening of recruitment for a Phase I/IIa clinical study in collaboration with Incyte to evaluate the combination of Bria-IMT™, retifanlimab, and epacadostat for advanced breast cancer treatment. This study follows previous treatments of two patients and aims to explore novel therapeutic combinations. BriaCell expresses optimism regarding the potential effectiveness and safety of this combination, underscoring its commitment to innovative cancer therapies.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company focused on immunotherapies for advanced breast cancer, announced two upcoming virtual presentations by CEO Dr. William V. Williams. He will present at the Access to Giving Conference on July 14, 2021, and the Q3 Investor Summit on August 17, 2021. Additionally, he will speak at the SNN Network Summer Virtual Event on August 18, 2021. Each event will offer opportunities for investor meetings and live webcasts.
BriaCell Therapeutics Corp. (BCTX, BCTXW) is expanding its breast cancer immunotherapy platform to include treatments for prostate, melanoma, and non-small cell lung cancers. The company has announced the development of three new therapies: Bria-Pros™, Bria-Mel™, and Bria-Lung™, leveraging an off-the-shelf personalized immunotherapy approach. Bria-OTS™ for advanced breast cancer is expected to enter clinical trials in 2021, while the new therapies are anticipated to commence trials in 2022. BriaCell aims to address the significant unmet medical needs in these cancer types.
BriaCell Therapeutics Corp. announced it raised US$12.88 million through the exercise of 2,425,300 warrants at US$5.3125 each. The funds will support the advancement of its clinical and research pipeline, focused on targeted immunotherapies for advanced breast cancer. Recently, BriaCell reported 12 months of overall survival benefit for patients in its Phase I/IIa study. The company aims to explore additional applications of its technology across other cancer types.